| Neoadjuvant PD-1 blockade in resectable lung cancer PM Forde, JE Chaft, KN Smith, V Anagnostou, TR Cottrell, MD Hellmann, ... New England Journal of Medicine 378 (21), 1976-1986, 2018 | 1965 | 2018 |
| Multisystem immune-related adverse events associated with immune checkpoint inhibitors for treatment of non–small cell lung cancer B Shankar, J Zhang, AR Naqash, PM Forde, JL Feliciano, KA Marrone, ... JAMA oncology 6 (12), 1952-1956, 2020 | 312 | 2020 |
| Transcriptional programs of neoantigen-specific TIL in anti-PD-1-treated lung cancers JX Caushi, J Zhang, Z Ji, A Vaghasia, B Zhang, EHC Hsiue, BJ Mog, ... Nature 596 (7870), 126-132, 2021 | 308 | 2021 |
| Resumption of immune checkpoint inhibitor therapy after immune-mediated colitis H Abu-Sbeih, FS Ali, AR Naqash, DH Owen, S Patel, GA Otterson, ... Journal of clinical oncology 37 (30), 2738-2745, 2019 | 171 | 2019 |
| Immune checkpoint inhibitor therapy in patients with preexisting inflammatory bowel disease H Abu-Sbeih, DM Faleck, B Ricciuti, RB Mendelsohn, AR Naqash, ... Journal of Clinical Oncology 38 (6), 576-583, 2020 | 157 | 2020 |
| The mutation-associated neoantigen functional expansion of specific T cells (MANAFEST) assay: a sensitive platform for monitoring antitumor immunity L Danilova, V Anagnostou, JX Caushi, JW Sidhom, H Guo, HY Chan, ... Cancer immunology research 6 (8), 888-899, 2018 | 144 | 2018 |
| Oral antibiotic use and risk of colorectal cancer in the United Kingdom, 1989–2012: a matched case–control study J Zhang, C Haines, AJM Watson, AR Hart, MJ Platt, DM Pardoll, ... Gut 68 (11), 1971-1978, 2019 | 128 | 2019 |
| Compartmental analysis of T-cell clonal dynamics as a function of pathologic response to neoadjuvant PD-1 blockade in resectable non–small cell lung cancer J Zhang, Z Ji, JX Caushi, M El Asmar, V Anagnostou, TR Cottrell, ... Clinical Cancer Research 26 (6), 1327-1337, 2020 | 110 | 2020 |
| Clinical activity of programmed cell death 1 (PD-1) blockade in never, light, and heavy smokers with non-small-cell lung cancer and PD-L1 expression≥ 50% JF Gainor, H Rizvi, EJ Aguilar, F Skoulidis, BY Yeap, J Naidoo, ... Annals of Oncology 31 (3), 404-411, 2020 | 98 | 2020 |
| A multidisciplinary toxicity team for cancer immunotherapy–related adverse events J Naidoo, J Zhang, EJ Lipson, PM Forde, K Suresh, KF Moseley, S Mehta, ... Journal of the National Comprehensive Cancer Network 17 (6), 712-720, 2019 | 87 | 2019 |
| Considerations for treatment duration in responders to immune checkpoint inhibitors TU Marron, AE Ryan, SM Reddy, S Kaczanowska, RH Younis, D Thakkar, ... Journal for immunotherapy of cancer 9 (3), 2021 | 85 | 2021 |
| Functional characterization of CD4+ T cell receptors crossreactive for SARS-CoV-2 and endemic coronaviruses AG Dykema, B Zhang, BA Woldemeskel, CC Garliss, LS Cheung, ... The Journal of clinical investigation 131 (10), 2021 | 75 | 2021 |
| Precision immuno-oncology: prospects of individualized immunotherapy for pancreatic cancer J Zhang, CL Wolfgang, L Zheng Cancers 10 (2), 39, 2018 | 59 | 2018 |
| Peripheral blood immune cell dynamics reflect antitumor immune responses and predict clinical response to immunotherapy M Hwang, JV Canzoniero, S Rosner, G Zhang, JR White, Z Belcaid, ... Journal for immunotherapy of cancer 10 (6), 2022 | 54 | 2022 |
| Intratumoral adaptive immunosuppression and type 17 immunity in mismatch repair proficient colorectal tumors NJ Llosa, B Luber, AJ Tam, KN Smith, N Siegel, AH Awan, H Fan, T Oke, ... Clinical Cancer Research 25 (17), 5250-5259, 2019 | 54 | 2019 |
| Immune-related adverse events requiring hospitalization: spectrum of toxicity, treatment, and outcomes A Balaji, J Zhang, B Wills, KA Marrone, H Elmariah, M Yarchoan, ... Journal of oncology practice 15 (9), e825-e834, 2019 | 45 | 2019 |
| Neoadjuvant nivolumab in resectable non-small cell lung cancer: extended follow-up and molecular markers of response. JE Reuss, KN Smith, V Anagnostou, J Zhang, M Zahurak, J Caushi, ... Journal of Clinical Oncology 37 (15_suppl), 8524-8524, 2019 | 31 | 2019 |
| Oral antibiotic use and chronic disease: long-term health impact beyond antimicrobial resistance and Clostridioides difficile J Queen, J Zhang, CL Sears Gut Microbes 11 (4), 1092-1103, 2020 | 22 | 2020 |
| Association between immune-related adverse events and clinical outcomes to programmed cell death protein 1/programmed death-ligand 1 blockade in SCLC B Ricciuti, AR Naqash, J Naidoo, K Sehgal, A Miller, K Kehl, ... JTO Clinical and Research Reports 1 (4), 100074, 2020 | 18 | 2020 |
| SARS-CoV-2 vaccination diversifies the CD4+ spike-reactive T cell repertoire in patients with prior SARS-CoV-2 infection AG Dykema, B Zhang, BA Woldemeskel, CC Garliss, R Rashid, ... EBioMedicine 80, 2022 | 15 | 2022 |
Jarushka NaidooAssistant Professor of Oncology, Johns Hopkins University在 jhmi.edu 的电子邮件经过验证
